Why measuring ‘quality of life’ on weight-loss drugs is harder than it sounds

A new study on blockbuster weight-loss drugs found no clinically meaningful improvement in quality of life for most patients — but outside experts say the way researchers measure “quality of life” itself may be part of the problem.

Marie Spreckley from the University of Cambridge said standardised tests might miss the personal victories that matter most to patients, since quality of life is highly individual and complex. The researchers behind the study, published in The BMJ, also acknowledged that many of the trials they examined were short-term, meaning more data is still needed to understand the long-term impacts of these newer drugs.

The analysis covered 262 clinical trials involving roughly 100,000 participants and 19 different medications, comparing standardised well-being questionnaires between drug users and people making lifestyle changes alone. The drug groups showed no clinically meaningful boost in quality-of-life scores, even as some medications — including tirzepatide and the unapproved CagriSema — delivered the largest weight-loss results.

José M. Ordovás from Tufts University said true success in treating obesity shouldn’t just be measured in kilograms, but in a patient’s overall health, daily function and genuine well-being — a framing echoed throughout the study’s conclusions.